Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1016215.RAbZpwjb0jaElL-XLaM-XXgfdXW5rRKTaMD-efA01-Ct8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1016215.RAbZpwjb0jaElL-XLaM-XXgfdXW5rRKTaMD-efA01-Ct8130_assertion type Assertion NP1016215.RAbZpwjb0jaElL-XLaM-XXgfdXW5rRKTaMD-efA01-Ct8130_head.
- NP1016215.RAbZpwjb0jaElL-XLaM-XXgfdXW5rRKTaMD-efA01-Ct8130_assertion description "[Using RT-PCR, quantitative, real-time RT-PCR, and fluorochrome oligonucleotide-based optical imaging, we established the level and pattern of expression of five of the identified known genes [Suppression of Tumorigenicity 13 (ST13), Cystatin 8 (CST-8), Dyskeratosis Congentia 1 (DKC1), Neuroendocrine Secretory Protein 55 (NESP55), Niemann-Pick Disease, type C2 (NP-C2)], and a gene with unknown function (16.7 kD Hypothetical Protein) in benign and atypical nevocytic lesions, advanced-stage melanomas, and melanoma-positive lymph nodes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1016215.RAbZpwjb0jaElL-XLaM-XXgfdXW5rRKTaMD-efA01-Ct8130_provenance.
- NP1016215.RAbZpwjb0jaElL-XLaM-XXgfdXW5rRKTaMD-efA01-Ct8130_assertion evidence source_evidence_literature NP1016215.RAbZpwjb0jaElL-XLaM-XXgfdXW5rRKTaMD-efA01-Ct8130_provenance.
- NP1016215.RAbZpwjb0jaElL-XLaM-XXgfdXW5rRKTaMD-efA01-Ct8130_assertion SIO_000772 14726712 NP1016215.RAbZpwjb0jaElL-XLaM-XXgfdXW5rRKTaMD-efA01-Ct8130_provenance.
- NP1016215.RAbZpwjb0jaElL-XLaM-XXgfdXW5rRKTaMD-efA01-Ct8130_assertion wasDerivedFrom befree-20150227 NP1016215.RAbZpwjb0jaElL-XLaM-XXgfdXW5rRKTaMD-efA01-Ct8130_provenance.
- NP1016215.RAbZpwjb0jaElL-XLaM-XXgfdXW5rRKTaMD-efA01-Ct8130_assertion wasGeneratedBy ECO_0000203 NP1016215.RAbZpwjb0jaElL-XLaM-XXgfdXW5rRKTaMD-efA01-Ct8130_provenance.